Dundee Sustainable Technologies: Appointment of a Director and Chair of the Audit Committee
MONTREAL, QUEBEC–(Marketwired – Oct. 27, 2015) – Dundee Sustainable Technologies Inc. (“DST“) (CSE:DST) is pleased to announce the appointment of Mr. Brian Howlett as a director of the Corporation and as Chair of the Audit Committee. Mr. Howlett is a graduate from Concordia University and is a Chartered Professional Accountant (“CPA, CMA”) with over 30 years of experience in senior financial roles. Mr. Howlett has served as senior officer of numerous public companies over his career. He currently serves as President and CEO of CR Capital Corp and on the Board of Directors of Superior Copper Corporation, both TSXV listed companies.
About Dundee Sustainable Technologies, a company controlled by Dundee Corporation
DST is engaged in the development of technologies for the treatment of complex material from the mining industry. DST proprietary processes are applied for the extraction of precious and base metals and for the stabilization of contaminants, such as arsenic, from ores, concentrates and tailings, which cannot be extracted or stabilized with conventional processes because of metallurgical issues or environmental considerations.
At present, DST utmost technological advances are associated to the extraction of precious metals using chlorination. This process provides a cyanide-free alternative for the exploitation of gold deposits. The primary benefits of the innovative technology are shorter processing times, a closed-loop operation eliminating the need for costly tailings pond, reduced environmental footprint related to inert and stable characteristics of the tailings.
The chlorination process developed by DST is a recognized “green technology” for which it was awarded a $5.7 million grant for the construction and operation of a $25 million demonstration plant. The commissioning of the demonstration plant, with a capacity of 15 tonnes per day of concentrate is expected to be completed by the end of October 2015 and will serve as a platform for the chlorination extraction technology on an industrial scale.
In addition, DST is currently constructing a pilot plant for its arsenic stabilization process which calls for the sequestration of the contaminants in a stable glass form. This process is becoming an attractive technique to segregate the toxic material and is therefore opening opportunities for materials considered to contain too much arsenic to be exploited or stabilized using conventional approaches.
DST has filed, published and granted patents for these processes in several countries.
FORWARD LOOKING STATEMENTS: This press release contains forward-looking statements that address future events and conditions, which are subject to various risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of numerous factors, some of which may be beyond the Corporation’s control. These factors include: general market and industry conditions, risks related to continuous operations and to commercialization of new technologies and other risks disclosed in the Corporation’s filings with Canadian Securities Regulators.
Forward-looking statements are based on the expectations and opinions of the Corporation’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Corporation expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Dundee Sustainable Technologies Inc.
John W. Mercer
President and CEO
(514) 866-6193
(514) 866-6001 # 239
info@dundeetechnologies.com
- Published in News Home
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start blogging!
- Published in Uncategorized
Sirona Biochem Presents New Results from Glycoprotein Program at BIO-Europe
Vancouver, British Columbia – October 26, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt/Xetra®: ZSB) (the “Company”) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe on November 4, 2015, at 10:15 am GMT at the International Congress Centre in Munich, Germany.
New results from the glycoprotein program for anti-aging and regenerative medicine will be presented, including positive efficacy data and potential new collaborative projects with cosmetic companies.
The conference is attended by major multinational pharmaceutical corporations and provides further opportunities to engage leading companies in partnering discussions for the newest skin-lightener, SBM-TFC-1067 (1067) and the glycoprotein compounds SBM-TFC-837,1165 and 1287.
“Clearly, we have significantly progressed partnering discussions for 1067 with a select group of companies that have been testing our compound since June, including formulation testing,” said Attila Hajdu. “This conference provides an opportunity to broaden the base of companies interested in licensing 1067. We were very excited about the interest from several new companies following Cosmetic 360 in Paris.”
Major companies attending the conference include Allergan, GSK, JT Pharma, Pfizer and many others.
BIO-Europe® is the EBD Group’s flagship conference, and continues the tradition of providing life science companies with high caliber partnering opportunities. BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO). For more information please visit the conference website at http://www.ebdgroup.com/bes.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
Sirona Presents New Results From Glycoprotein Program at BIO-Europe
Sirona Biochem Presents New Results From Glycoprotein Program at BIO-Europe
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (the “Company“) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe on November 4, 2015, at 10:15 am GMT at the International Congress Centre in Munich, Germany.
New results from the glycoprotein program for anti-aging and regenerative medicine will be presented, including positive efficacy data and potential new collaborative projects with cosmetic companies.
The conference is attended by major multinational pharmaceutical corporations and provides further opportunities to engage leading companies in partnering discussions for the newest skin-lightener, SBM-TFC-1067 (1067) and the glycoprotein compounds SBM-TFC-837,1165 and 1287.
“Clearly, we have significantly progressed partnering discussions for 1067 with a select group of companies that have been testing our compound since June, including formulation testing,” said Attila Hajdu. “This conference provides an opportunity to broaden the base of companies interested in licensing 1067. We were very excited about the interest from several new companies following Cosmetic 360 in Paris.”
Major companies attending the conference include Allergan, GSK, JT Pharma, Pfizer and many others.
BIO-Europe® is the EBD Group’s flagship conference, and continues the tradition of providing life science companies with high caliber partnering opportunities. BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO). For more information please visit the conference website at http://www.ebdgroup.com/bes.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
- Published in Blog, Life Sciences
DealNet Announces Results of 2015 Annual and Special Meeting of Shareholders
TORONTO, ONTARIO–(Marketwired – Oct. 23, 2015) – DealNet Capital Corp. (“DealNet” or the “Company”) (TSX VENTURE:DLS), is pleased to announce the results of its annual and special meeting of shareholders held on October 23, 2015 in Toronto, Ontario.
All of the proposed nominees were elected as directors of the Company to serve until the next annual meeting of shareholders. Based on individual voting, each director received 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the total votes cast for his or her election as a director. The directors of the Company are Harold Bridge, Victoria Davies, Michael Hilmer, Brent Houlden, John Radford and Dr. Steven Small.
Shareholders also voted in favour of all proposed resolutions and special resolutions, including resolutions fixing the number of directors at six, empowering the directors of the Company to determine from time to time the number of directors of the Company and the number of directors of the Company to be elected at an annual meeting, re-appointing Ernst and Young LLP as the Company’s auditors, ratifying and approving the Company’s Employee Stock Option Plan, confirming the Company’s new by-law, approving a reduction in the Company’s stated capital and contributed surplus and creating a new class of preferred shares.
A total of 83,017,149 shares were voted, representing 58.27{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the issued and outstanding shares of the Company as of September 8, 2015 (the record date for the meeting).
About DealNet Capital Corp.
DealNet is an engagement enabled consumer finance company that is initially focused on home improvement finance solutions including heating ventilation and air conditioning financing and leasing. DealNet leverages its large scale customer service and engagement technology platform to attract home improvement dealers by providing front and back office services to them resulting in dealer origination growth.
For additional information please visit www.sedar.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release
- Published in Dealnet News
OrganiGram Provides Shareholder Update and Q1 Guidance
MONCTON, NEW BRUNSWICK–(Marketwired – Oct. 21, 2015) – OrganiGram Holdings Inc. (TSX VENTURE:OGI) (OTCQX:OGRMF) (the “Company“) is pleased to provide an update to shareholders.
With the results of the recent Federal election, OrganiGram is well positioned to service the recreational marijuana market, as the only large, organic medical marijuana producer.
“We are confident that our products will be welcomed by all retail distribution points, as a significant portion of the consumers will want to experience an organic option,” said Roger Rogers, President & CFO.
In addition, OrganiGram is continuing to experience an active and growing base of new patients. It has always been a top priority for the Company to ensure the timely registration of all new clients. It is an OrganiGram policy to guarantee patients supply of product at the time of registration and with each and every time a prescription refill is ordered. With the addition of new grow rooms and capacity, the Company has been able to continue their monthly double-digit growth and are quickly approaching 2,000 active registered patients.
The Company is currently in the process of preparing the Audited Year-End Financial Statements and anticipates their release to be in early December. As previously stated in a news release issued on July 30th, the Company was targeting Q4 sales of $500,000. However, this target was exceeded and, thus, based on experience, Management has increased their expectations and guidance for Q1 to be at $900,000 in sales.
“Our growth trend is continuing as planned and we are rolling out our business initiatives with precision. We are receiving very positive feedback on our products and our customer service. All of this aligned with an exceptional management team are providing the desired results for all our stakeholders”, said Roger Rogers, President & CFO.
As announced on September 2, 2015, the Company received approval of four additional grow rooms, increasing the annual production capacity of the facility to 2,100kg. Over the last month, the rooms have been brought online and are entering the Company’s production cycle. The initial harvest from these new rooms is expected in February of 2016.
Following the Supreme Court of Canada ruling in June and subsequent changes to the Health Canada regulations; OrganiGram has been preparing to provide its patients with the option to purchase Medical Marijuana in the form of oil extracts. It is anticipated that the Company will begin shipping oil extract to patients in the near future.
In an ongoing effort to provide the best quality service to patients, the Company has recently completed multiple internal improvements.
Mr. Rogers states, “We recently announced in our newsletter that we have re-branded the company to incorporate our Maritime heritage and theme, updating our website as well as introducing new client offerings while keeping in mind ease of use for our clients. These changes include the branding of strain names, comprehensive product details, and the launching of OGI Buzz to stay updated with the company, as well as additional items included in our welcome and registration packages. These changes will to help onboard our clients smoothly while providing a superior customer experience to all.”
About OrganiGram Holdings Inc.
OrganiGram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, OrganiGram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.
On behalf of the board of directors,
Denis Arsenault
Director and CEO
OrganiGram Holdings Inc.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of operations — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Brett Allan
Director of Investor Relations
OrganiGram Holdings Inc.
(647) 229-6627
www.organigram.ca
- Published in Organigram Holdings
Equitas Resources Completes Four Holes at Garland
Equitas Resources Corp. Updates Exploration Program on its Garland Nickel-Copper Property
Equitas Resources Corp. (TSXv: EQT) (FSE: T6UN) (“Equitas” or the “Company”) is pleased to provide an update on its exploration program at the Garland nickel-copper property in Labrador, Canada.
To date, four NQ diamond drill holes, totaling 1515m have been completed. The objective of the drill program is to evaluate the remaining ten areas of conductivity prospective for nickel-copper sulphides identified through the VTEM Plus airborne survey. Of these anomalies, drilling has tested anomalies D, C, J and Q. A total of 173 samples have been sent to Activation Laboratories in Ancaster, ON for analysis, and samples are being selected for petrographic study.
Field evaluation of the twelve VTEM anomaly areas continues with Crone large loop PEM surveys. A total of 30 line km of Crone large loop Pulse Electromagnetic Survey (PEM) has been read on anomalies A, B, C, Q, G, J and I. Results of Crone borehole PEM surveys are being interpreted. Field operations to explore the remaining anomalies will continue until conditions deteriorate into winter.
In addition, the Company is conducting petrographic analysis on several samples from anomalies D and J. While weather conditions have created general delays in the program, field operations are continuing on site. A full geophysics and drilling update will be provided upon receipt and interpretation of results.
“We are satisfied with the progress of work completed to date, and await full results from the current program. Despite a very tough financing climate, Equitas is well-funded to execute on our plans to evaluate all anomalies identified on the Garland property.” said Everett Makela, Equitas’ VP Exploration.
NI 43-101 Disclosure
Everett Makela, P. Geo., VP Exploration for Equitas Resources Corp., a Qualified Person as defined by National Instrument 43-101, supervised the preparation of the technical information in this news release.
About Equitas Resources Corp.
Equitas Resources is a Canadian-based mineral exploration company with a focus on nickel, copper, platinum group metals (PGM) and cobalt. The Companies Garland Property is 23,386 hectares and located in the Voisey’s Bay district of Labrador, Canada.
OrganiGram Holdings Inc. Comments on Colorado Pesticide Lawsuit
MONCTON, NEW BRUNSWICK–(Marketwired – Oct. 19, 2015) – OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OTCQX:OGRMF) (the “Company”) would like to provide its position pertaining to the medical marijuana industry’s use of pesticides during the growing process.
As highlighted by the recent lawsuits filed against a marijuana company operating in Colorado, the use of pesticides within the medical marijuana industry could potentially pose serious health concerns for patients.
OrganiGram has chosen to grow our products with Organic methods and thus produces the highest quality product available, without the use of harmful chemical pesticides. As such, the Company remains a proud holder of the ECOCERT Canada Certification, which validates the organic process under which OrganiGram produces medical marijuana.
“Producing a product with natural components, chemical free and organic processes is one of the core principles on which OrganiGram is based. I believe the recent US lawsuit shed further light on the benefits of the products that we provide to patients. We look forward to continuing to supply medicine that differentiates us from our peers and is the best solution for our clients,” said Roger Rogers, President & CFO.
About OrganiGram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.
Please visit www.organigram.ca for more information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
OrganiGram Holdings Inc.
Brett Allan
Director of Investor Relations
(416) 907-4148
brett@organigram.ca
www.organigram.ca
- Published in Organigram Holdings
Dealnet Announces Issuance of Stock Options
TORONTO, ONTARIO–(Marketwired – Oct. 19, 2015) – Dealnet Capital Corp. (“Dealnet” or the “Company”) (TSX VENTURE:DLS) announces that the Board of Directors granted 500,000 stock options to an officer of the Company pursuant to the Company’s stock option plan. The stock options will vest over a period of 18 months and will be exercisable for a period of five years at an exercise price of $0.91 per stock option.
About Dealnet Capital Corp.
Dealnet is an engagement enabled consumer finance company that is initially focused on home improvement finance solutions including heating ventilation and air conditioning financing and leasing. Dealnet leverages its large scale customer service and engagement technology platform to attract home improvement dealers by providing front and back office services to them resulting in dealer origination growth.
For additional information please visit www.sedar.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
- Published in Dealnet News
First Berlin – Sirona Biochem Corp. Research Update
First Berlin Equity Research has published a research update on Sirona Biochem Corp. (SBM:tsxv) (ISIN: CA82967M1005). Analyst Ellis Acklin reiterated his BUY rating and maintained his CAD 0.90 price target.
This is an abbreviated summary. The full text of this story is included just below.
Abstract:
Sirona published Q3/15 figures for the period ending 31 July (FYE: October). As expected, the period centred mainly on R&D activities and no sales were generated. Although operating costs increased Q/Q, the nine month results were in line with our expectations. In the recent quarter, Sirona also reported the scale-up of TFC-1067 and we learned that TFC-837 is currently being evaluated by a leading cosmetic company. The company also recently received a cash boost from exercised warrants. We remain positive on the progress of Sirona’s pipeline and reiterate our BUY recommendation with a CAD0.90 price target.
Financial Forecasts: |
2012 |
2013 |
2014 |
2015E |
2016E |
2017E |
Revenue (CADm) |
0.00 |
0.00 |
0.00 |
0.00 |
7.26 |
18.51 |
EBIT (CADm) |
-3.02 |
-2.64 |
-3.48 |
-3.80 |
3.66 |
15.02 |
EPS (diluted) (CAD) |
-0.04 |
-0.03 |
-0.03 |
-0.03 |
0.02 |
0.08 |
FCF (CADm) |
-2.22 |
-2.62 |
-2.09 |
-4.10 |
1.74 |
10.86 |
First Berlin – Sirona Biochem Corp. Equity Research – October 15, 2015.
- Published in Blog, Business, Life Sciences